Back to Search
Start Over
Finerenone meets primary endpoint in Phase III FINEARTS-HF cardiovascular outcomes study in patients with heart failure with mildly reduced or preserved ejection fraction
- Source :
- European Union News. August 6, 2024
- Publication Year :
- 2024
-
Abstract
- Germany: Bayer AG has issued the following press release: The Phase III study FINEARTS-HF, evaluating the efficacy and safety of finerenone versus placebo when added to usual therapy in patients [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- European Union News
- Publication Type :
- News
- Accession number :
- edsgcl.804291881